Johnson & Johnson Q3 Results - Q3 Top Pharma Company Earnings Reports

View Johnson & Johnson's Q3 Earnings Report

FiercePharma says: Market reaction to Johnson & Johnson's earnings announcement reflects an overall worry about cost-cutting versus sales growth. Yes, J&J beat expectations, posting earnings of $1.20 per share, about 7 cents higher than analysts had estimated. But third-quarters sales came in at $15.1 billion, which fell short of those same estimates. At press time, the stock had fallen 2.62 percent, or $1.64, to $60.89. Read more of our coverage here...

Highlights:

  • Sales of $15.1 Billion Decreased 5.3% Versus 2008 Third Quarter
  • EPS of $1.20 increased 2.6% Versus 2008 Third Quarter

Check out J&J's current earnings estimates from CNN Money

J&J's Website: http://www.jnj.com/connect/

Johnson & Johnson Q3 Results - Q3 Top Pharma Company Earnings Reports
Read more on

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.